论文部分内容阅读
从细菌学角度出发,结核病的现代化疗应考虑两个问题。1是避免以基因突变方式产生耐药菌株,2是因其缓慢或间歇性生长,分枝杆菌持续存活。经基因突变方式,对一种抗结核药产生白发耐药菌的机率约为1×10~(-6),而对两种既往未曾接触过的抗结核药产生耐药性突变菌的机率等于两者的乘积1×10~(-12)在菌量较多的活动性空洞中,结核杆菌的数目很少超过1×10~9。因此,联合应用两种抗结核药物,一般足以防止通过基因突变形成耐药菌株的危险。另一方面,采用长程疗法(为期18个月),可解决分枝杆菌持续存活的问题。如未产生耐药性,利福平(Rifampin,RFP)与异烟肼(INH)联合用药9个月,疗效也很满
From a bacteriological point of view, two problems should be considered in modern chemotherapy of tuberculosis. 1 is to avoid the generation of drug-resistant strains by genetic mutation, 2 because of its slow or intermittent growth, and mycobacteria continue to survive. The gene mutation method, the probability of an anti-TB drug white hair-resistant bacteria is about 1 × 10 -6, while the two never had contact with anti-TB drug-resistant mutants probability The product of the two is equal to 1 × 10 ~ (-12), and the number of Mycobacterium tuberculosis rarely exceeds 1 × 10 ~ 9 in the active bacteria with more bacteria. Therefore, the combination of two anti-TB drugs is generally sufficient to prevent the risk of developing drug-resistant strains by genetic mutation. On the other hand, the use of long-term therapy (for a period of 18 months) can solve the problem of persistent mycobacterium survival. In the absence of drug resistance, Rifampin (RFP) and isoniazid (INH) combined medication for 9 months, the effect is also very full